Halozyme grants CEO Helen Torley $10 million performance stock award tied to share price
Halozyme's Compensation Committee approved a one-time performance-based restricted stock unit grant to CEO Dr. Helen Torley on December 4, 2025, with a grant date fair value of $10 million. The shares vest only if the company's average share price reaches set levels over a four-year period and Torley remains employed through the fourth anniversary of the grant. The award ties a large part of her pay to sustained share price gains.
Key points
- Grant approved December 4, 2025 under the 2021 Stock Plan; grant date fair value of $10 million
- Vesting ranges from 50% to 200% of target, based on average share price hitting $115, $130, $145 or $170
- Shares that become eligible must still vest through the fourth anniversary of the grant date; voluntary resignation or retirement before then forfeits performance-based vested shares
- Full award agreement to be filed as an exhibit to the 10-K for fiscal year ending December 31, 2025
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 09, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.